Insulet: closed‑loop momentum
New study outcomes supporting a fully closed‑loop insulin pump for Type 2 diabetes have put Insulet in the spotlight and coincided with a large uptick in short interest — signaling investor focus on a potential commercial growth runway for automated insulin delivery in T2D report. If adoption follows the study, automated pumps could materially change insulin workflows for insulin‑requiring T2D patients.
EVOLUTION 2 participants achieved an average 68% time‑in‑range while using the fully closed‑loop algorithm without requiring bolus insulin dosing. businesswire.com The multicenter feasibility study enrolled 24 adults (age 16–70) from a diverse New Zealand cohort, reported a mean diabetes duration of 16 years, and included people on basal‑only or basal‑bolus regimens with HbA1c up to 12.0%. investors.insulet.com Insulet said the EVOLUTION 2 data were presented at the 19th ATTD conference in Barcelona by Dr. Martin de Bock, positioning the results as feasibility evidence to refine the Omnipod algorithm and user experience. businesswire.com The company plans to start its pivotal EVOLVE trial in 2026, pursue a 510(k) filing in 2027, and targets a commercial launch of the Omnipod fully closed‑loop system in 2028. investors.insulet.com Short interest jumped to 2,817,783 shares as of February 27, 2026 — an 86.4% increase from the Feb. 12 print — equal to roughly 4.0% of shares short and a short‑interest ratio of 2.4 days, per MarketBeat’s March 13 report. marketbeat.com Insulet issued the EVOLUTION 2 release on March 11, 2026, and the mid‑March short‑interest spike has coincided with the company’s published timeline for pivotal testing and a planned market entry, crystallizing investor focus on the commercial runway for Omnipod in insulin‑requiring Type 2 patients. businesswire.com
